• potency
  • We examined the relative potency of hydralazine in large-calibre vessels from sHF patients and investigated its purported ability to reduce vascular superoxide (never before examined in humans). (bmj.com)
  • patients
  • No information is available on the relationship of age to the effects of hydralazine in geriatric patients. (mayoclinic.org)
  • A total of 143 patients (alpha 0.5, power 0.8)with metastatic, persistent or recurrent cervical cancer without previous systemic treatment will be randomized to cisplatin topotecan + placebo or cisplatin topotecan hydralazine valproate for 6 courses every 3 weeks. (clinicaltrials.gov)
  • plasma
  • Hydralazine may also increase plasma renin concentration, resulting in fluid retention. (wikipedia.org)
  • Increased plasma norepinephrine accompanies persistent tachycardia after hydralazine. (ahajournals.org)
  • The temporal discordance of the changes of both heart rate and plasma norepinephrine relative to the reduction in blood pressure and the significant linear correlation between the increases in heart rate and plasma norepinephrine concentration suggest that continued activation of the peripheral sympathetic nervous system contributes to the persistent tachycardia seen after the administration of hydralazine. (ahajournals.org)
  • concentration
  • cumulative concentration response curves to hydralazine (1 nmol/l to 10 μmol/l) were constructed in vessels preconstricted with phenylephrine (3 μmol/l) and mantained in physiological conditions. (bmj.com)
  • Cummulative concentration response cueves to hydralazine in human saphenous vein (SV) and internal mammary artery (IMA). (bmj.com)
  • Significant
  • Conclusions We have demonstrated, for the first time in human blood vessels, that hydralazine reduces vascular superoxide production, potentially a novel and therapeutically significant mechanism of action, which may enhance nitric oxide-mediated vasodilatation. (bmj.com)
  • increase
  • Drugs subject to a strong first-pass effect such as β-blockers may increase the bioavailability of hydralazine. (wikipedia.org)
  • Hydralazine and magnesium valproate associated to cisplatin topotecan will increase progression-free survival from 4.6 to 7.6 months as compared with the same regimen of chemotherapy plus placebo. (clinicaltrials.gov)
  • standard
  • To determine the superiority of epigenetic therapy with hydralazine and valproate plus standard cisplatin topotecan against placebo plus cisplatin topotecan upon progression-free survival. (clinicaltrials.gov)
  • list
  • Anti-histone antibody Lupus erythematosus Hydralazine Discoid lupus erythematosus List of cutaneous conditions Rubin, Robert L. (2005-02-04). (wikipedia.org)
  • therapy
  • Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Recurrent and Metastatic Cervical Cancer. (clinicaltrials.gov)